INT125578

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 14
Disease Relevance 7.59
Pain Relevance 0.53

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (IGF1) extracellular space (IGF1) extracellular region (IGF1)
Anatomy Link Frequency
peripheral nerves 3
plasma 2
liver 2
thyroid 2
pituitary 2
IGF1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 45 99.52 Very High Very High Very High
headache 5 95.72 Very High Very High Very High
antagonist 2 84.40 Quite High
Somatostatin 19 81.92 Quite High
Clonidine 9 80.68 Quite High
depression 12 5.00 Very Low Very Low Very Low
carpal tunnel syndrome 2 5.00 Very Low Very Low Very Low
Hippocampus 2 5.00 Very Low Very Low Very Low
cva 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Thyroiditis 9 99.18 Very High Very High Very High
Acromegaly 5 98.86 Very High Very High Very High
Chronic Fatigue Syndrome 104 98.72 Very High Very High Very High
Thyroid Disease 252 98.30 Very High Very High Very High
Pituitary Cancer 3 97.04 Very High Very High Very High
Chronic Disease 9 96.64 Very High Very High Very High
Stress 22 96.36 Very High Very High Very High
Hypothyroidism 18 96.08 Very High Very High Very High
Headache Disorders 1 95.72 Very High Very High Very High
Malabsorption Syndromes 9 95.52 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Spontaneous normalisation of FT4 concentration on the level close to the values obtained before rhGH administration, observed in the majority of patients, presented parallel to further increase of IGF-I secretion.
Positive_regulation (increase) of Localization (secretion) of IGF-I
1) Confidence 0.60 Published 2010 Journal Thyroid Res Section Body Doc Link PMC2858102 Disease Relevance 0.07 Pain Relevance 0.04
According to our observations, the therapy with rhGH led to a similar increase of IGF-I secretion and of its bioavailability in the patients with different forms of disorders of GH secretion and activity.
Positive_regulation (increase) of Localization (secretion) of IGF-I associated with bioavailability
2) Confidence 0.60 Published 2010 Journal Thyroid Res Section Body Doc Link PMC2858102 Disease Relevance 0 Pain Relevance 0.05
Moreover, Schmid et al. [29] showed that, during L-T4 replacement, IGF-I and acid-labile subunit secretion increased in the patients with both primary and central hypothyroidism, while IGFBP-3 - only in those with primary hypothyroidism.
Positive_regulation (increased) of Localization (secretion) of IGF-I associated with hypothyroidism and thyroid disease
3) Confidence 0.60 Published 2010 Journal Thyroid Res Section Body Doc Link PMC2858102 Disease Relevance 1.02 Pain Relevance 0
As a matter of fact, a direct effect of thyroid function on IGF-I secretion was not fully confirmed in our study, as there were no significant differences in an increase of IGF-I secretion between the euthyroid children and those, who presented with hypothyroidism during rhGH administration.
Positive_regulation (increase) of Localization (secretion) of IGF-I in thyroid associated with thyroid disease
4) Confidence 0.60 Published 2010 Journal Thyroid Res Section Body Doc Link PMC2858102 Disease Relevance 0.75 Pain Relevance 0
However, further increase of IGF-I secretion on the same rhGH dose was observed after 1 year of rhGH therapy, with respect to the values obtained after 3-6 months of treatment.
Positive_regulation (increase) of Localization (secretion) of IGF-I
5) Confidence 0.60 Published 2010 Journal Thyroid Res Section Body Doc Link PMC2858102 Disease Relevance 0.66 Pain Relevance 0
Interestingly enough, a good response to rhGH administration - at least, twofold increase of IGF-I secretion, leading to normalisation of its level in plasma - was observed in each case, thus allowing exclusion of GH insensitivity and pointing at decreased bioactivity of endogenous GH in these children.
Positive_regulation (increase) of Localization (secretion) of IGF-I in plasma
6) Confidence 0.43 Published 2010 Journal Thyroid Res Section Body Doc Link PMC2858102 Disease Relevance 0.45 Pain Relevance 0.06
In children with decreased IGF-I secretion and normal GH peak (both in nocturnal profile and after pharmacological stimulation), IGF-I generation test was performed after exclusion of other causes of IGF-I deficiency, not related to GH secretion disorders and GH action (like malabsorption syndromes, liver diseases, malnutrition, other severe chronic diseases).
Positive_regulation (performed) of Localization (secretion) of IGF-I in liver associated with appetite loss, liver disease, malabsorption syndromes and chronic disease
7) Confidence 0.43 Published 2010 Journal Thyroid Res Section Body Doc Link PMC2858102 Disease Relevance 0.38 Pain Relevance 0.08
Similarly, Bona et al. [28] documented that in the patients with hypothyroidism - both congenital and caused by thyroiditis - L-T4 replacement led to physiological increase of IGF-I and IGFBP-3 secretion.
Positive_regulation (increase) of Localization (secretion) of IGF-I associated with thyroiditis and thyroid disease
8) Confidence 0.43 Published 2010 Journal Thyroid Res Section Body Doc Link PMC2858102 Disease Relevance 0.99 Pain Relevance 0
Despite similar IGF-I secretion increase, the improvement of HV presented significantly lower in children with HypoT than in those who remained euthyroid all the time.


Positive_regulation (increase) of Localization (secretion) of IGF-I
9) Confidence 0.35 Published 2010 Journal Thyroid Res Section Abstract Doc Link PMC2858102 Disease Relevance 0.07 Pain Relevance 0.04
Cholinergic neurotransmission stimulates growth hormone and insulin-like growth factor I secretions, which plays an important role in the regenerative functions of the peripheral nerves and skeletal muscles.35 Taking together these findings, increased cholinergic activity by galantamine treatment might trigger well-being independently of cortisol levels in some patients.
Positive_regulation (stimulates) of Localization (secretions) of insulin-like growth factor I in peripheral nerves
10) Confidence 0.29 Published 2009 Journal Psychiatry Investigation Section Body Doc Link PMC2796068 Disease Relevance 0.64 Pain Relevance 0
Cholinergic neurotransmission stimulates growth hormone and insulin-like growth factor I secretions, which plays an important role in the regenerative functions of the peripheral nerves and skeletal muscles.35 Taking together these findings, increased cholinergic activity by galantamine treatment might trigger well-being independently of cortisol levels in some patients.
Positive_regulation (stimulates) of in skeletal muscles Localization (secretions) of insulin-like growth factor I in peripheral nerves
11) Confidence 0.10 Published 2009 Journal Psychiatry Investigation Section Body Doc Link PMC2796068 Disease Relevance 0.64 Pain Relevance 0
The morbidity and excess mortality of acromegaly are usually the consequence of the metabolic actions of excess GH and IGF-I secretion, while only in rare patients mortality is due to the mass effects of the pituitary tumour.
Positive_regulation (excess) of Localization (secretion) of IGF-I in pituitary associated with acromegaly and pituitary cancer
12) Confidence 0.08 Published 2004 Journal Minerva Endocrinol. Section Abstract Doc Link 15765031 Disease Relevance 1.32 Pain Relevance 0.10
Bowers and colleagues showed that chronic repeated injections or subcutaneous infusions of GH-releasing peptide-2 (GHRP-2) could stimulate and maintain increases in episodic GH secretion and IGF-I (Bowers et al 2004).
Positive_regulation (increases) of Localization (secretion) of IGF-I
13) Confidence 0.05 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2544358 Disease Relevance 0.40 Pain Relevance 0.08
As with previous studies, there was a sustained increase in IGF-I and episodic GH secretion, and an increase in lean body mass (Thorner et al 2006).
Positive_regulation (increase) of Localization (secretion) of IGF-I in body
14) Confidence 0.05 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2544358 Disease Relevance 0.21 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox